About Go Therapeutics
Go Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2013. Tumor-specific antibodies are developed using O-glycan structures for cancer immunotherapy. Go Therapeutics has raised $5 million across 1 funding round from investors including Salubris Biotherapeutics. Go Therapeutics offers products and services including Discovery Platform and Super-Clean Targets. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Go Therapeutics is focussed on developing tumor-specific antibodies for cancer immunotherapy. It has developed a proprietary platform to identify the sites of O-linked glycosylation on tumor-associated proteins and use the accessibility of O-glycans in the plasma membrane to develop novel hybrid epitopes that are part protein and O-glycan structure which are the targets for immunotherapeutics. Its lead candidate is in pre-clinical trials for breast cancer and other aggressive tumors.
- Headquarters Cambridge, United States
- SectorsHealthcare
- Email••••••••
- Website gotherapeutics.com
- Social LinkedIn
- Total Equity Funding$5M (USD)
in 1 rounds
- Latest Funding Round$5M (USD), Series A
Aug 2017
- Investors
Products & Services of Go Therapeutics
Go Therapeutics offers a comprehensive portfolio of products and services, including Discovery Platform and Super-Clean Targets.
Platform to identify super-clean cancer targets for therapies
Exclusive targets for enhancing solid tumor treatments
Funding Insights of Go Therapeutics
Go Therapeutics has successfully raised a total of $5M through 1 strategic funding round. The most recent funding activity was a Series A round of $5 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 1
- Last Round Series A — $5M
- First Round $5M
(Aug 2017)
- Investors Count 1
All 1 funding rounds of Go Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $5M | Series A | – | Salubris Biotherapeutics | – |
1 investors in total: 1 institutional.
Investors in Go Therapeutics
Go Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Salubris Biotherapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Antibody therapeutics are developed for cancer, cardiovascular, and metabolic diseases. | 2016 | salubrisbio.com | Gaithersburg, United States |
Investor details for Go Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Go Therapeutics
5 people are tracked at Go Therapeutics (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Hans Wandall | Scientific Co-Founder & CSO | Leadership |
Constantine Theodoropulos | Co-Founder & CEO | Leadership |
Aaron C. Groen | Director of Biology | Leadership |
Nisha shrestha, Ph.D. | Senior Scientist | Team |
Boris Klebanov | Scientist | Team |
Complete people profiles for Go Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Go Therapeutics
2 dated milestones of Go Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Go Therapeutics is founded.
- Funding First funding round of $5.0M.
Competitors of Go Therapeutics
Go Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Go Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Go Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Go Therapeutics
Complete news archive for Go Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Go Therapeutics
Go Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Go Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Go Therapeutics is a funded company, having raised a total of $5M across 1 funding round to date. The company's 1st funding round was a Series A of $5M, raised on Aug 2017.
Go Therapeutics is focussed on developing tumor-specific antibodies for cancer immunotherapy. It has developed a proprietary platform to identify the sites of O-linked glycosylation on tumor-associated proteins and use the accessibility of O-glycans in the plasma membrane to develop novel hybrid epitopes that are part protein and O-glycan structure which are the targets for immunotherapeutics. Its lead candidate is in pre-clinical trials for breast cancer and other aggressive tumors.
Go Therapeutics offers Discovery Platform and Super-Clean Targets.
Go Therapeutics has 1 investor. Key investors include Salubris Biotherapeutics.